Thomas Areschoug

Corporate Officer/Principal at XINTELA AB

52 year

Health Technology

Commercial Services

Profile

Thomas Areschoug was the founder of Minervax ApS, a company founded in 2010 where he held the title of Director.
He is currently working as the Chief Business Officer at Xintela AB since 2017.
In the past, he worked as the Manager-Business Development at Invest in Skane AB.

Thomas Areschoug active positions

Companies	Position	Start
XINTELA AB	Corporate Officer/Principal	2017-02-28

All active positions of Thomas Areschoug

Former positions of Thomas Areschoug

Companies	Position	End
Invest in Skane AB Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden.	Corporate Officer/Principal	-
Minervax ApS Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.	Founder	-

See the detail of Thomas Areschoug's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Thomas Areschoug's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
XINTELA AB	Health Technology

Private companies	2
Invest in Skane AB Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden.	Commercial Services
Minervax ApS Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.	Health Technology